Since BridgeBio scored FDA approval for cardiomyopathy drug Attruby 15 months ago, its launch has progressed smoothly as the treatment has proven a worthy competitor to Pfizer’s powerhouse Vyndamax ...

BridgeBio has revealed new pivotal trial data for Attruby (acoramidis) along with results from an indirect comparison to Pfizer’s Vyndamax (tafamidis), as the former company looks to continue ...